91 related articles for article (PubMed ID: 8645031)
41. Recurrent episodes of recall dermatitis of irradiated breast after LHRH agonist administration.
Kostadima L; Pentheroudakis G; Pavlidis N
J BUON; 2011; 16(1):183-4. PubMed ID: 21674876
[No Abstract] [Full Text] [Related]
42. [Effectiveness of skin icing for reducing pain associated with luteinizing hormone-releasing hormone agonist injection].
Nomura T; Tsunoda K; Ohta S; Doi K; Miyoshi K; Hasegawa Y; Mizutani M
Gan To Kagaku Ryoho; 2014 Feb; 41(2):221-4. PubMed ID: 24743201
[TBL] [Abstract][Full Text] [Related]
43. No rules without exception: long-term complete remission observed in a study using a LH-RH agonist in platinum-refractory ovarian cancer.
Paskeviciute L; Roed H; Engelholm S
Gynecol Oncol; 2002 Sep; 86(3):297-301. PubMed ID: 12217751
[TBL] [Abstract][Full Text] [Related]
44. Use of a long-acting gonadotropin-releasing hormone agonist for treatment of steroid cell tumors of the ovary.
Wang PH; Chao HT; Lee WL
Fertil Steril; 1998 Feb; 69(2):353-5. PubMed ID: 9496356
[TBL] [Abstract][Full Text] [Related]
45. No rules without exception: a long-term complete remission observed in a study using a LH-RH agonist in platinum-refractory ovarian cancer.
Paskeviciute L; Roed H; Engelholm A
Eur J Cancer; 2002 Nov; 38 Suppl 6():S73. PubMed ID: 12409084
[No Abstract] [Full Text] [Related]
46. Goserelin reduces ovarian failure associated with breast cancer chemotherapy, study shows.
Mayor S
BMJ; 2015 Mar; 350():h1274. PubMed ID: 25752307
[No Abstract] [Full Text] [Related]
47. Breast cancer: Shielding the ovaries from chemotherapy in breast cancer.
Hutchinson L
Nat Rev Clin Oncol; 2015 May; 12(5):252. PubMed ID: 25801817
[No Abstract] [Full Text] [Related]
48. The complete control and possible cure of a recurrent carcinoma of the breast by means of hormonal therapy over a 22-year period: a case report.
Erskine JM
Am J Clin Oncol; 1998 Dec; 21(6):624-5. PubMed ID: 9856670
[No Abstract] [Full Text] [Related]
49. May there be a role for hormonal manipulation for treatment of hormone receptor negative breast cancer?
Onder Eren O; Uysal Sonmez O; Oyan B
J BUON; 2015; 20(5):1380. PubMed ID: 26537091
[No Abstract] [Full Text] [Related]
50. Ovarian protection during adjuvant chemotherapy.
Oktay K; Rodriguez-Wallberg K; Munster P
N Engl J Med; 2015 Jun; 372(23):2268-9. PubMed ID: 26039611
[No Abstract] [Full Text] [Related]
51. Ovarian protection during adjuvant chemotherapy.
Peccatori FA
N Engl J Med; 2015 Jun; 372(23):2268. PubMed ID: 26039610
[No Abstract] [Full Text] [Related]
52. Ovarian protection during adjuvant chemotherapy.
Moore HC; Unger JM; Albain KS
N Engl J Med; 2015 Jun; 372(23):2269-70. PubMed ID: 26039609
[No Abstract] [Full Text] [Related]
53. [LH-RH analogues in metastatic breast cancer: first results].
Terzoli E; Izzo F; Nisticò C; Lucatelli S; Ranuzzi M
G Ital Oncol; 1988; 8(2):59-63. PubMed ID: 3065224
[No Abstract] [Full Text] [Related]
54. Pregnancy during gonadotrophin-releasing hormone agonist therapy.
Uncu G; Benderli S; Esmer A
Aust N Z J Obstet Gynaecol; 1996 Nov; 36(4):484-5. PubMed ID: 9006841
[No Abstract] [Full Text] [Related]
55. Metastatic breast carcinoma presenting with profound hypocalcemia.
Cooksley T; Banerjee M; Younis N
South Med J; 2010 May; 103(5):480-1. PubMed ID: 20375959
[TBL] [Abstract][Full Text] [Related]
56. [Importance of bone scintigraphy in the after-care of breast cancer].
Dtsch Med Wochenschr; 1986 Nov; 111(48):1860-1. PubMed ID: 3023006
[No Abstract] [Full Text] [Related]
57. [GnRH analogs for treatment of ovarian cancer].
Kośmider M
Ginekol Pol; 1996 Oct; 67(10):499-503. PubMed ID: 9289430
[TBL] [Abstract][Full Text] [Related]
58. [Metastases of breast cancer in the late period after radical treatment].
Iakivchuk IaIa
Klin Khir (1962); 1985 May; (5):62. PubMed ID: 4021346
[No Abstract] [Full Text] [Related]
59. [Mental neuropathy as a manifestation of systemic cancer. Description of a case].
Sanz Ortiz J; Cancelo Suárez P; Fariñas Alvarez C; Arribas Alpuente L
Med Clin (Barc); 1984 Nov; 83(16):677-9. PubMed ID: 6513659
[No Abstract] [Full Text] [Related]
60. [Chemoembolization of symptomatic bone metastases: technical considerations and therapeutic effectiveness].
Clarençon F; Cormier E; Di Maria F; Sourour NA; Szatmary Z; Rose M; Chiras J
J Radiol; 2011 Sep; 92(9):814-20. PubMed ID: 21944240
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
